N/A N=6 Excimer Light Treatment for Idiopathic Guttate Hypomelanosis: A Pilot Study
Idiopathic Guttate Hypomelanosis
Primary: Efficacy Outcome — 2.31; 1.15 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=75,771 Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo
Vitiligo · Melanoma (Skin) · Nonmelanoma Skin Cancer
Primary: Number of New Onset Skin Cancer in Adult People Diagnosed With Vitiligo — 133; 812 Participants
N/A N=10 Early Molecular Changes in Vitiligo After Narrowband Ultraviolet Therapy
Vitiligo · Dermatology/Skin - Other
Primary: Molecular Changes From NB-UVB Therapy
N/A N=43 Study to Test Genetic Alterations Among Different Dermoscopic Types of Melanocytic Nevi.
Nevi
Primary: Frequency of BRAF Mutations Among Nevi — 6; 19 BRAF mutations
Phase 2 N=6 High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia
Retinal Diseases · Telangiectasis
Primary: Visual Acuity Change From Baseline to Month 12 of the Study — 0.1; -0.05 LogMAR Unit
N/A N=39,374 Investigating Healthcare Disparities in Vitiligo
Vitiligo
Primary: Risk of Depression Within Patients With Vitiligo — 1412; 5395 Events
N/A N=10 Dermatosis Papulosa Nigra
Facial Dermatoses · Seborrheic Keratoses
Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance
Phase 4 N=6 Can We Miss Pigmented Lesions in Psoriasis Patients?
Psoriasis · Melanoma · Non-melanoma Skin Cancer
Primary: The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques. — 0 participants
N/A N=13 The Efficacy of Hand Narrow-Band Ultraviolet B (NBUVB) Versus Excilite Treatment in Vitiligo After Minigrafting on the Dorsal Hands
Vitiligo
Primary: Percent Repigmentation of Target Lesion — 0.21; 0.17 percentage of repigmentation
N/A N=11 Blue Light Phototherapy
Grover's Disease · Psoriasis Vulgaris
Primary: Efficacy of Blue Light Therapy for Patients With Grover's Disease — 27; 6 lesion count
Phase 3 N=215 Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Plaque Psoriasis
Primary: The Percentage of Participants With Treatment Success at Week 8 — 45.33; 12.51 percentage of participants
N/A N=12 Fractionated 1927nm Laser for Hyperpigmentation in Fitzpatrick Skin Phototypes V and VI
Hyperpigmentation
Primary: Change in Spots - Front of Face (Part 1) — 53.60; 58.47; 56.44 spots
Phase 2 N=152 Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis
Psoriasis
Primary: Percent of Subjects With Treatment Success, Defined by at Least a 2 Grade Improvement From Baseline in the Investigator Global Assessment (IGA) Score Equating to Clear…
N/A N=30 Nonablative Fractional Diode Laser for Treatment of Pigmented Lesions
Pigmented Skin Lesion
Primary: Pigmented Lesion Improvement by Blinded Evaluation — 41 Observations
Phase 2 N=19 A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis
Congenital Ichthyosis
Primary: Number of Participants With Adverse Events (AEs) in Part 1 of Trial (Weeks 0-8) — 7; 7; 5; 5 participants
N/A N=20 Laser Removal of Age (Sun) Spots on Hands
Solar Lentigines
Primary: Median VAS Improvement Score as Assessed by Blinded Physician Reviewers — 1.5 units on a scale — p=<0.0001
N/A N=25 PHNA, Efficacy of Tretinoin Cream on Post-phototherapy Hyperpigmentation
Vitiligo
Primary: The Degree of Hyperpigmentation at 12 Weeks — 56.8; 57.6; 51.0; 54.3 score on a scale — p=0.002
N/A N=40 Potential Impact of Patient Vitamin D Status in AK Response to MAL-PDT
Actinic Keratosis
Primary: Changes From Baseline in Actinic Keratosis - Lesion Base Count. — 1.15; 2.65; 1.15; 2.60 lesions — p=<0.001
Early Phase 1 N=13 An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses
Ichthyosis
Primary: Reduction in Total Ichthyosis Severity Score — -12.2 units on a scale
Phase 2 N=16 Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)
Idiopathic Solar Urticaria
Primary: Assessment of the Minimal Urticaria Dose (MUD) on Each Test Site, After Application of the Test Products — 4.33; 3.93; 3.80; 3.67 Photodermatosis Protection Factor
Phase 3 N=217 Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis
Plaque Psoriasis
Primary: Percentage of Participants With Treatment Success at Week 8 — 36.5; 8.13 percentage of participants
Phase 3 N=213 Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis
Plaque Psoriasis
Primary: Percentage of Participants With Treatment Success at Week 8 — 38.41; 11.99 percentage of participants
Phase 2 N=9 Treatment of Oral Premalignant Lesions With 5-ALA PDT
Leukoplakia · Erythroplakia
Primary: Maximum Tolerated Dose — 8 J/cm2
N/A N=8 308nm Excimer Laser for Treatment of Fingernail Psoriasis
Nail Psoriasis
Primary: Modified NAPSI Score (Nail Psoriasis Severity Index) — 6.3; 6.0 units on a scale
N/A N=32 Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors
Skin Rash
Primary: Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and…
Phase 3 N=203 Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Plaque Psoriasis
Primary: The Percentage of Participants With Treatment Success at Week 8 — 35.76; 6.98 percentage of participants
Phase 2 N=185 Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo
Non-Segmental Vitiligo
Primary: Percent Change From Baseline in Facial-Vitiligo Area Scoring Index (F-VASI) at Week 24 — -14.36; -21.96; -35.63; -33.96 Percent change from baseline — p=0.304
Phase 2 N=61 Urticaria Facticia Treatment With Omalizumab (UFO)
Symptomatic Dermographism
Primary: Change in Provocation Thresholds From Baseline to Day 70 in Urticaria Factitia Patients After Treatment With Omalizumab Compared to Placebo — -1.8; -2.0; -0.6 wheal…
N/A N=24 Study of the 532 nm KTP Laser for the Treatment of Poikiloderma of Civatte
Poikiloderma of Civatte · Dyschromia · Pigmentation Disorders
Primary: Severity Assessment Score — -0.06; 0.2 score on a scale
Phase 2 N=212 Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis
Plaque Psoriasis
Primary: Percentage of Participants With Treatment Success of a 2-Grade IGA Score Improvement From Baseline and an IGA Score of Clear or Almost Clear at Week 8 — 52.5; 33.3…